Asia Pacific Theranostics Market

Asia Pacific Theranostics Market Size (2024 to 2029)

According to the report, the Asia Pacific Theranostics Market Size was valued at USD 22.40 Million in 2024 and is also predicted to reach USD 43.57 Million by 2029, growing at a CAGR of 14.23% during the forecast period 2024 to 2029.

Theranostics is expected to increase fast as cancer incidence continues to rise and side-effects of procedures like chemotherapy continue to be difficult for practitioners. Furthermore, because recovery is often slow and requires time away from patients' daily routines, post-cancer care promises lucrative growth. 

Rising disposable income, a significant population, and more access to healthcare are projected to generate a substantial increase soon in the Asia Pacific theranostics industry. As we look ahead, Europe's growing older population, technologically improved healthcare systems, and possibilities like universal care are projected to fuel significant development. In addition, the global theranostics market is being driven by the rising prevalence of life-threatening and chronic diseases, the demand for new chemotherapeutic therapies, and better disease diagnostics.

Furthermore, the growing potential of therapeutically functional nanomaterials in biological imaging and therapy is likely to drive market expansion. Due to rising awareness and use of companion diagnostics, particularly for cancers, the Asia-Pacific theranostics market is predicted to increase over the forecast period rapidly. Global firms are also putting a lot of effort into developing partnerships and collaborations with regional players to introduce strategic products and increase product sales margins. 

Theranostics is the combination of diagnostics and medication therapy to speed up the creation of a more effective and less expensive drug. Cancer has emerged as a significant worry for the healthcare sector. Developing an effective medicine with minimal side effects has become an urgent requirement, requiring close collaboration between drug developers and the diagnostic industry. Theranostics is a new discipline attracting much attention from regulatory organizations and the healthcare industry.

The high costs of treatment and the fact that it is still experimental are expected to be essential impediments to its development. Furthermore, healthcare prices and a lack of information about post-cancer therapies are expected to be roadblocks in countries like the Asia Pacific.

This research report on the APAC Theranostics Market has been segmented and sub-segmented into the following categories.

Asia Pacific Theranostics Market By Disease Type

• Neurological Disorders
• Cardiovascular Diseases
• Immunological Disorders
• Oncology
• Others

Asia Pacific Theranostics Market By Technology

• Polymerase Chain Reaction (PCR)
• Immunohistochemistry
• In Situ Hybridization
• Sequencing
• Others

Asia Pacific Theranostics Market By End-User

• Hospitals
• Diagnostics Laboratories
• Others

Asia Pacific Theranostics Market By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the Asia Pacific is the world's second-largest market for theranostics. In this region, China theranostics market and India theranostics market are the developing nations among the public due to rapidly improving medical infrastructure, increasing medical tourism, newer rules implemented by governing bodies, and increased awareness; the APAC region is predicted to grow at the fastest rate. 

In addition, Theranostics market growth is expected to be aided by better collaboration between medication and diagnostics companies. Another significant driver fueling the development of the global theranostics market is the reduction in costs and time necessary for medical trials supervised by pharmaceutical industries. In addition, the worldwide theranostics industry is being driven by the rising incidence of cardiovascular and cancer diseases.

Furthermore, ongoing research initiatives in these domains contribute significantly to market growth. Again, the growing number of strategic alliances and partnerships is expected to move the overall industry forward at a rapid rate. The global increase in the development of novel companion diagnostic tests, the mounting adoption of companion diagnostic tests by end-users, the increasing collaborations and partnerships by prominent market participants to develop innovative companion diagnostics, and the rising burden of chronic diseases are all factors driving the market forward.

KEY MARKET PLAYERS

Top companies leading in the APAC Theranostics Market profiled in the report are Abbott Laboratories, AmeriPath, Dickinson and Company, BIOTEC Laboratories, Dade Behring, Dianon Systems, Dynacare Laboratories, Enterix, Focus Diagnostics, Pfizer, and Beckman Coulter.,